EMERYVILLE, Calif., May 25, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat during the William Blair 42nd Annual Growth Stock Conference in Chicago, Illinois on Monday June 6, 2022 at 4:40 p.m. C.T.
A live webcast of the presentation can be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations and a replay will be available following the event.
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Derek Cole, President
Investor Relations Advisory Solutions
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-william-blair-42nd-annual-growth-stock-conference-301555194.html
SOURCE Dynavax Technologies